Overview of the Upcoming ASN Kidney Week Presentations
Biopharma company Sobi has announced that new data will be shared at ASN Kidney Week 2025, taking place November 5–9. The conference program includes one-year efficacy data for pegylated C3G therapy pegcetacoplan (marketed as Aspaveli/Empaveli) in two glomerular diseases—the rare kidney conditions C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). In addition, NASP (nano-antibody selective plasmapheresis) results in uncontrolled gout will be presented. The announcements underscore Sobi’s ongoing commitment to expanding the evidence base for complement-targeting therapies and related plasma exchange approaches in kidney disease management.
What pegcetacoplan Brings to C3G and IC-MPGN
C3G is characterized by dysregulation of the complement system, which can drive inflammation and progressive kidney damage. Pegcetacoplan is a pegylated inhibitor of the complement component C3, designed to reduce overactive complement activity and protect kidney tissue. For patients with C3G and IC-MPGN, long-term data showing sustained improvement or stabilization in kidney function, biomarkers, and symptomatology are crucial for guiding treatment strategies where options have been historically limited.
At ASN Kidney Week 2025, the one-year data set will be highlighted to address questions such as durability of response, safety over extended exposure, and the impact on renal biomarkers. Clinicians will be looking for signals that pegcetacoplan can alter the disease course, potentially translating to slower progression to kidney failure or reduced reliance on supportive therapies. As with other complement inhibitors, monitoring for adverse events and infections remains a key component of evaluating real-world applicability.
IC-MPGN: A Related Target in Glomerulopathy
IC-MPGN shares mechanistic features with C3G, driven by immune complex deposition and dysregulated complement activity. The inclusion of IC-MPGN data in the presentation agenda suggests a broader assessment of pegcetacoplan’s therapeutic reach. Physicians specializing in nephrology and rare kidney disorders will be keen to see whether the one-year outcomes in IC-MPGN corroborate findings seen in C3G, potentially supporting a unified approach to disease management within the spectrum of complement-mediated glomerulopathies.
NASP in Uncontrolled Gout: A Separate Yet Related Approach
In addition to kidney-focused research, the NASP program is designed to address uncontrolled gout through a controlled program of plasma exchange techniques. NASP is explored as a complementary strategy for patients whose disease remains refractory to standard urate-lowering therapies. The ASN Kidney Week 2025 data presentation will include new NASP outcome data, shedding light on efficacy, safety, and patient-reported outcomes in this challenging patient population. While gout primarily affects joints, comorbidity with kidney disease is common, making NASP results of interest to a wider audience seeking integrated therapies for inflammatory and metabolic disorders.
Why This Update Matters for Patients and Clinicians
For patients with C3G or IC-MPGN, the availability of robust, long-term data on pegcetacoplan could influence treatment discussions and decision-making. For clinicians, the conference findings may provide deeper insights into which patients are most likely to benefit, how to monitor response over time, and how to balance benefits with potential risks. In parallel, NASP data may offer a new avenue for addressing uncontrolled gout in patients who face complex clinical scenarios where kidney health and urate management intersect.
What to Expect from the ASN Kidney Week 2025 Presentations
While the detailed results will be disclosed in the formal conference presentations and corresponding publications, attendees can anticipate a focused set of analyses examining efficacy endpoints, safety signals, and biomarker trends over a 12-month period. The composite picture from pegcetacoplan across C3G and IC-MPGN, together with NASP outcomes, is likely to shape future research directions and potentially inform regulatory and payer discussions about extending access to these therapies for eligible patients.
About Sobi and the Therapies Mentioned
Sobi, listed on the Stockholm Stock Exchange (SOBI), develops and markets therapies for rare and complex diseases. Aspaveli and Empaveli refer to the same pegylated C3 inhibitor used in glomerulopathy research, while NASP data reflect the company’s exploration of plasmapheresis-based strategies for inflammatory and metabolic conditions. ASN Kidney Week serves as a key venue for disseminating pivotal safety and efficacy findings to the nephrology community.
